Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gain Therapeutics, Inc. (GANX)
USD1.67
-0.01 (-0.60%)
US NASDAQ Healthcare Biotechnology
Address
4800 Montgomery Lane 20814
Bethesda, MD, US
Bethesda, MD, US
CEO
Gene Mack
Website
gaintherapeutics.com
IPO
2021-03-19
CIK 1819411 ISIN US36269B1052
Description
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.67
-0.01 (-0.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
832.1K
Beta
0.16
Float Shares
41.36M
Free Float %
97.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.47% | +3.17% | +3.17% | -25.29% | -44.29% | -39.44% | +10.17% | -58.12% | -81.93% | -82.59% | -82.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
1.67
Low
8.00
+379.0%
Consensus
9.00
+438.9%
Median
9.00
+438.9%
High
10.00
+498.8%
DCF (Unlevered)
0.61
-63.5%
DCF (Levered)
0.61
-63.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
8.33
+398.8%
|
| All Time | 5 |
7.80
+367.1%
|
Quality scores
Altman Z-Score
0.55
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+31.5% ★ Q1'26: +18.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +958.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+44.1% Q1'26: +47.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
165.0K
est: 149.0K (+10.7%)
|
140.1K
est: 125.0K (+12.1%)
|
55.2K
est: 276.0K (-80.0%)
|
—
est: 33.3K (-100.0%)
|
—
est: 40.0K (-100.0%)
|
50.0K
50.0K – 50.0K
+25.0% YoY
|
225.0K
225.0K – 225.0K
+350.0% YoY
|
100.29M
100.29M – 100.29M
+44,474.5% YoY
|
48.07M
48.07M – 48.07M
-52.1% YoY
|
134.57M
134.57M – 134.57M
+180.0% YoY
|
| EBITDA |
-13.81M
est: -89.4K (-15,348.2%)
|
-17.71M
est: -75.0K (-23,517.2%)
|
-22.17M
est: -165.6K (-13,287.4%)
|
-20.27M
est: -6.7K (-303,928.2%)
|
-18.62M
est: -8.0K (-232,637.3%)
|
-10.0K
-10.0K – -10.0K
-25.0% YoY
|
-45.0K
-45.0K – -45.0K
-350.0% YoY
|
-20.06M
-20.06M – -20.06M
-44,475.5% YoY
|
-9.61M
-9.61M – -9.61M
+52.1% YoY
|
-26.91M
-26.91M – -26.91M
-180.0% YoY
|
| EBIT |
-13.83M
est: -89.4K (-15,365.5%)
|
-17.78M
est: -75.0K (-23,602.7%)
|
-22.25M
est: -165.6K (-13,337.9%)
|
-20.35M
est: -6.7K (-305,189.4%)
|
-18.71M
est: -8.0K (-233,813.0%)
|
-10.0K
-10.0K – -10.0K
-25.0% YoY
|
-45.0K
-45.0K – -45.0K
-350.0% YoY
|
-20.06M
-20.06M – -20.06M
-44,475.5% YoY
|
-9.61M
-9.61M – -9.61M
+52.1% YoY
|
-26.91M
-26.91M – -26.91M
-180.0% YoY
|
| Net Income |
-13.89M
est: -36.01M (+61.4%)
|
-17.59M
est: -32.30M (+45.5%)
|
-22.27M
est: -36.61M (+39.2%)
|
-20.41M
est: -32.24M (+36.7%)
|
-20.16M
est: -21.24M (+5.1%)
|
-18.30M
-19.65M – -16.94M
+13.8% YoY
|
-24.67M
-30.17M – -19.16M
-34.8% YoY
|
-25.06M
-30.99M – -19.12M
-1.6% YoY
|
-494.5K
-494.5K – -494.5K
+98.0% YoY
|
54.07M
54.07M – 54.07M
+11,033.3% YoY
|
| SGA |
6.83M
est: 10.84M (-37.0%)
|
9.54M
est: 9.10M (+4.9%)
|
10.79M
est: 20.08M (-46.3%)
|
9.56M
est: 2.05M (+367.1%)
|
8.50M
est: 2.46M (+246.0%)
|
3.07M
3.07M – 3.07M
+25.0% YoY
|
13.81M
13.81M – 13.81M
+350.0% YoY
|
6.16B
6.16B – 6.16B
+44,474.5% YoY
|
2.95B
2.95B – 2.95B
-52.1% YoY
|
8.26B
8.26B – 8.26B
+180.0% YoY
|
| EPS |
-1.37
est: -1.57 (+12.9%)
|
-1.48
est: -1.41 (-4.8%)
|
-1.71
est: -1.60 (-6.9%)
|
-0.89
est: -0.96 (+7.6%)
|
-0.61
est: -0.64 (+5.3%)
|
-0.56
-0.60 – -0.51
+13.8% YoY
|
-0.74
-0.92 – -0.58
-33.7% YoY
|
-0.76
-0.94 – -0.58
-2.4% YoY
|
-0.02
-0.02 – -0.02
+98.0% YoY
|
1.64
1.64 – 1.64
+11,033.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-19.37M
OE per share TTM
-0.56
Owner's Yield
-23.52%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
906.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
46
Total invested
15.82M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
46
-6 vs prev Q
New positions
9
Closed positions
16
Increased
20
Reduced
9
Put/Call ratio
0.34
Calls held
91.4K
Puts held
31.4K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | POTOMAC CAPITAL MANAGEMENT, INC. | 1.01M +1.0M (+100.0%) | 3.25B +3.3B (+100.0%) | 2.89% +2.886 pp | 2.61% +2.613 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 2 | MARSHALL WACE, LLP | 1.66M +1.5M (+849.3%) | 5.35M +5.0M (+1,627.0%) | 4.75% +4.173 pp | 0.00% +0.005 pp | USD3.09 +4.2% | 5 qtrs — |
| 3 | JONES FINANCIAL COMPANIES LLLP | 702.2K +25.4K (+3.8%) | 2.26M +1.0M (+86.6%) | 2.01% -0.224 pp | 0.00% +0.001 pp | USD1.92 +67.7% | 7 qtrs — |
| 4 | VANGUARD GROUP INC | 569.9K +35.5K (+6.7%) | 1.84M +889.3K (+94.0%) | 1.63% -0.133 pp | 0.00% +0.000 pp | USD2.40 +34.2% | 12 qtrs — |
| 5 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 568.6K +250.0K (+78.5%) | 1.83M +1.3M (+224.6%) | 1.62% +0.575 pp | 0.00% +0.003 pp | USD2.45 +31.4% | 5 qtrs — |
| 6 | DME CAPITAL MANAGEMENT, LP | 566.1K +— (+0.0%) | 1.82M +820.9K (+81.9%) | 1.62% -0.248 pp | 0.06% +0.025 pp | USD3.83 -15.9% | 8 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 397.9K +53.8K (+15.6%) | 1.28M +673.3K (+110.5%) | 1.14% +0.003 pp | 0.00% +0.000 pp | USD2.92 +10.3% | 17 qtrs — |
| 8 | JANE STREET GROUP, LLC | 242.3K +169.9K (+234.5%) | 780.3K +652.1K (+508.5%) | 0.69% +0.454 pp | 0.00% +0.000 pp | USD2.79 +15.4% | 2 qtrs — |
| 9 | BLACKROCK, INC. | 209.6K +93.4K (+80.4%) | 674.8K +469.2K (+228.2%) | 0.60% +0.216 pp | 0.00% +0.000 pp | USD2.43 +32.5% | 6 qtrs — |
| 10 | CRESSET ASSET MANAGEMENT, LLC | 160.0K +160.0K (+100.0%) | 515.2K +515.2K (+100.0%) | 0.46% +0.457 pp | 0.00% +0.002 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 11 | STATE STREET CORP | 157.5K +66.4K (+72.9%) | 507.3K +346.0K (+214.5%) | 0.45% +0.150 pp | 0.00% +0.000 pp | USD2.86 +12.6% | 8 qtrs — |
| 12 | MORGAN STANLEY | 147.6K -8.1K (-5.2%) | 475.2K +199.7K (+72.5%) | 0.42% -0.091 pp | 0.00% +0.000 pp | USD1.99 +61.8% | 20 qtrs — |
| 13 | LPL FINANCIAL LLC | 106.6K +106.6K (+100.0%) | 343.1K +343.1K (+100.0%) | 0.30% +0.304 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 14 | NORTHERN TRUST CORP | 102.0K +13.6K (+15.4%) | 328.4K +172.0K (+109.9%) | 0.29% +0.000 pp | 0.00% +0.000 pp | USD2.72 +18.4% | 14 qtrs — |
| 15 | UBS GROUP AG | 81.1K -59.6K (-42.3%) | 261.2K +12.2K (+4.9%) | 0.23% -0.232 pp | 0.00% +0.000 pp | USD1.91 +68.6% | 20 qtrs — |
| 16 | COLONY GROUP, LLC | 77.9K +77.9K (+100.0%) | 250.7K +250.7K (+100.0%) | 0.22% +0.223 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 17 | HRT FINANCIAL LP | 55.7K +36.0K (+182.4%) | 179.0K +145.0K (+426.5%) | 0.16% +0.094 pp | 0.00% +0.000 pp | USD2.71 +18.8% | 2 qtrs — |
| 18 | GROUP ONE TRADING, L.P. | 54.2K +37.4K (+222.9%) | 174.4K +144.7K (+487.3%) | 0.15% +0.100 pp | 0.00% +0.000 pp | USD2.77 +16.2% | 3 qtrs — |
| 19 | SIMPLEX TRADING, LLC | 47.9K +47.9K (+100.0%) | 154.4K +154.4K (+100.0%) | 0.14% +0.137 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 10 qtrs — |
| 20 | BENEDICT FINANCIAL ADVISORS INC | 38.0K +3.0K (+8.6%) | 122.4K +60.4K (+97.5%) | 0.11% -0.007 pp | 0.03% +0.012 pp | USD2.06 +56.3% | 5 qtrs — |
| 21 | OMERS ADMINISTRATION CORP | 37.3K +37.3K (+100.0%) | 120.1K +120.1K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.001 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 22 | PRELUDE CAPITAL MANAGEMENT, LLC | 35.8K +— (+0.0%) | 115.3K +51.9K (+81.9%) | 0.10% -0.016 pp | 0.01% +0.004 pp | USD14.92 -78.4% | 20 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 32.5K +32.5K (+100.0%) | 104.6K +104.6K (+100.0%) | 0.09% +0.093 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 24 | POINT72 ASSET MANAGEMENT, L.P. | 32.5K +32.5K (+100.0%) | 104.6K +104.6K (+100.0%) | 0.09% +0.093 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 30.6K +30.6K (+100.0%) | 98.5K +98.5K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 3 qtrs — |
| 26 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 30.0K +— (+0.0%) | 96.6K +43.5K (+81.9%) | 0.09% -0.013 pp | 0.00% +0.001 pp | USD2.16 +49.1% | 19 qtrs — |
| 27 | CITADEL ADVISORS LLC | 26.1K +26.1K (+100.0%) | 84.0K +84.0K (+100.0%) | 0.07% +0.075 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 28 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 23.0K +23.0K (+100.0%) | 74.2K +74.2K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.002 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 29 | GSA CAPITAL PARTNERS LLP | 20.5K +20.5K (+100.0%) | 66.0K +66.0K (+100.0%) | 0.06% +0.059 pp | 0.01% +0.006 pp | USD3.22 +0.0% | 3 qtrs — |
| 30 | OLIVER LUXXE ASSETS LLC | 20.3K +20.3K (+100.0%) | 65.2K +65.2K (+100.0%) | 0.06% +0.058 pp | 0.01% +0.010 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 31 | APOLLON WEALTH MANAGEMENT, LLC | 19.8K +19.8K (+100.0%) | 63.8K +63.8K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.001 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 32 | RENAISSANCE TECHNOLOGIES LLC | 17.4K -108.7K (-86.2%) | 56.0K -167.2K (-74.9%) | 0.05% -0.366 pp | 0.00% 0.000 pp | USD1.79 +79.9% | 3 qtrs — |
| 33 | WEALTHSPIRE ADVISORS, LLC | 16.9K +16.9K (+100.0%) | 54.4K +54.4K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 34 | SANDHILL CAPITAL PARTNERS LLC | 15.4K +— (+0.0%) | 49.6K +22.3K (+81.9%) | 0.04% -0.007 pp | 0.00% +0.002 pp | USD1.78 +80.9% | 6 qtrs — |
| 35 | ENGINEERS GATE MANAGER LP | 14.6K +14.6K (+100.0%) | 47.1K +47.1K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.001 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 36 | MILLENNIUM MANAGEMENT LLC | 14.0K +14.0K (+100.0%) | 45.1K +45.1K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 37 | COMMONWEALTH EQUITY SERVICES, LLC | 12.7K +12.7K (+100.0%) | 40.9K +40.9K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 38 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 15.6K +— (+0.0%) | 39.7K +8.2K (+26.2%) | 0.04% -0.007 pp | 0.00% +0.000 pp | USD1.77 +81.9% | 2 qtrs — |
| 39 | KESTRA ADVISORY SERVICES, LLC | 12.0K +— (+0.0%) | 38.6K +17.4K (+81.9%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD1.77 +81.9% | 2 qtrs — |
| 40 | SPROTT INC. | 12.0K +12.0K (+100.0%) | 38.6K +38.6K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.001 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 41 | NEWEDGE ADVISORS, LLC | 10.6K +— (+0.0%) | 34.1K +15.4K (+81.9%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD1.91 +68.6% | 4 qtrs — |
| 42 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.9K +4.8K (+232.3%) | 22.1K +18.4K (+504.6%) | 0.02% +0.013 pp | 0.00% +0.000 pp | USD2.80 +15.0% | 18 qtrs — |
| 43 | MAI CAPITAL MANAGEMENT | 4.4K +— (+0.0%) | 14.2K +6.4K (+81.9%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD2.16 +49.1% | 5 qtrs — |
| 44 | BANK OF AMERICA CORP /DE/ | 3.9K +1.0 (+0.0%) | 12.6K +5.7K (+82.0%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD3.47 -7.2% | 8 qtrs — |
| 45 | WELLS FARGO & COMPANY/MN | 2.7K +— (+0.0%) | 8.5K +3.8K (+81.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.82 -15.7% | 16 qtrs — |
| 46 | BNP PARIBAS ARBITRAGE, SNC | 2.4K +2.4K (+100.0%) | 7.7K +7.7K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 47 | FNY INVESTMENT ADVISERS, LLC | 2.0K +2.0K (+100.0%) | 6.0K +6.0K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.002 pp | USD3.22 +0.0% | 1 qtrs NEW |
| 48 | STATE OF WYOMING | 1.4K +1.4K (+100.0%) | 4.6K +4.6K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.001 pp | USD3.22 +0.0% | 3 qtrs — |
| 49 | LARSON FINANCIAL GROUP LLC | 10.00 +10.0 (+100.0%) | 32.00 +32.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.20 +0.6% | 1 qtrs NEW |
| 50 | XTX TOPCO LTD | — -54.2K (-100.0%) | — -95.9K (-100.0%) | 0.00% -0.179 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 51 | KOVITZ INVESTMENT GROUP PARTNERS, LLC | — -47.6K (-100.0%) | — -84.2K (-100.0%) | 0.00% -0.157 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 52 | JPMORGAN CHASE & CO | — -26.3K (-100.0%) | — -46.5K (-100.0%) | 0.00% -0.087 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 53 | HIGHTOWER ADVISORS, LLC | — -11.6K (-100.0%) | — -20.5K (-100.0%) | 0.00% -0.038 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 54 | SQUAREPOINT OPS LLC | — -38.5K (-100.0%) | — -68.2K (-100.0%) | 0.00% -0.127 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 55 | SRS CAPITAL ADVISORS, INC. | — -3.3K (-100.0%) | — -5.8K (-100.0%) | 0.00% -0.011 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 56 | TWO SIGMA SECURITIES, LLC | — -27.3K (-100.0%) | — -48.4K (-100.0%) | 0.00% -0.090 pp | 0.00% -0.007 pp | USD— | 4 qtrs SOLD |
| 57 | BISON WEALTH, LLC | — -10.8K (-100.0%) | — -19.8K (-100.0%) | 0.00% -0.035 pp | 0.00% -0.002 pp | USD— | 4 qtrs SOLD |
| 58 | VIRTU FINANCIAL LLC | — -54.0K (-100.0%) | — -96.0K (-100.0%) | 0.00% -0.178 pp | 0.00% -0.005 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 259.5K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 821.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
250.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+250,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | Mack Gene | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.86 | 372.0K | 200,000 | D | ↗ |
| 2026-03-24 | Fuggetta Gianluca | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 1.86 | 93.0K | 50,000 | D | ↗ |
| 2025-06-24 | Riley Jeffrey Scott | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | RICHMAN ERIC I | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | Melincoff Gwen A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | Islam Khalid | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | HASLER HANS PETER | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-06-24 | GOLDSTEIN DOV A MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | D | ↗ |
| 2025-03-20 | Mack Gene | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 2.29 | 458.0K | 200,000 | D | ↗ |
| 2025-03-20 | Fuggetta Gianluca | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 2.29 | 114.5K | 50,000 | D | ↗ |
| 2025-01-06 | Mack Gene | Director / Officer | A-Award | A | Stock Option (right to buy) | 271,325 | 2.44 | 662.0K | 271,325 | D | ↗ |
| 2024-08-09 | Mack Gene | Officer | P-Purchase | A | Common Stock | 14,400 | 1.01 | 14.5K | 14,400 | — | ↗ |
| 2024-08-09 | Islam Khalid | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.00 | 49.9K | 50,000 | — | ↗ |
| 2024-07-01 | RICHMAN ERIC I | Director | P-Purchase | A | Common Stock | 12,000 | 1.21 | 14.5K | 289,629 | — | ↗ |
| 2024-06-24 | Riley Jeffrey Scott | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | RICHMAN ERIC I | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | Melincoff Gwen A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | Islam Khalid | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | HASLER HANS PETER | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-06-24 | GOLDSTEIN DOV A MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2024-04-08 | Mack Gene | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 3.56 | 712.0K | 200,000 | — | ↗ |
| 2024-04-05 | Mack Gene | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-28 | Riley Jeffrey Scott | Director | P-Purchase | A | Common Stock | 30,000 | 3.86 | 115.8K | 30,000 | — | ↗ |
| 2024-03-26 | Alder Matthias | Director / Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 25,763 | — | ↗ |
| 2024-03-21 | Fuggetta Gianluca | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 4.37 | 218.5K | 50,000 | — | ↗ |
| 2024-03-21 | Alder Matthias | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 370,000 | 4.37 | 1.62M | 370,000 | — | ↗ |
| 2023-12-21 | Alder Matthias | Director / Officer | S-Sale | D | Common Stock | 206 | 2.46 | 506.76 | 5,286 | — | ↗ |
| 2023-12-20 | Alder Matthias | Director / Officer | M-Exempt | D | Restricted Stock Units | 637 | 0.00 | — | 7,013 | — | ↗ |
| 2023-12-07 | Alder Matthias | Director / Officer | S-Sale | D | Common Stock | 1,820 | 2.50 | 4.6K | 4,855 | — | ↗ |
| 2023-10-01 | Alder Matthias | Director / Officer | M-Exempt | D | Restricted Stock Units | 825 | 0.00 | — | 9,075 | — | ↗ |
| 2023-09-20 | RICHMAN ERIC I | Director | M-Exempt | A | Common Stock | 54,900 | 0.00 | — | 272,629 | — | ↗ |
| 2023-09-20 | Alder Matthias | Director / Officer | M-Exempt | D | Restricted Stock Units | 2,550 | 0.00 | — | 7,650 | — | ↗ |
| 2023-07-01 | Alder Matthias | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,300 | 0.00 | — | 9,900 | — | ↗ |
| 2023-06-23 | Riley Jeffrey Scott | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-06-23 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-06-23 | Melincoff Gwen A | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-06-23 | Islam Khalid | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-06-23 | HASLER HANS PETER | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-06-23 | GOLDSTEIN DOV A MD | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 4.50 | 47.3K | 10,500 | — | ↗ |
| 2023-04-10 | Ballantyne Charles Evan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-23 | Fuggetta Gianluca | Officer | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 4.84 | 72.6K | 15,000 | — | ↗ |
| 2023-03-23 | Calabrese Salvatore | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 4.84 | 242.0K | 50,000 | — | ↗ |
| 2023-03-23 | Alder Matthias | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 4.84 | 726.0K | 150,000 | — | ↗ |
| 2022-12-12 | Fuggetta Gianluca | Officer | — | D | Employee Stock Option (right to buy) | 10,000 | 3.47 | 34.7K | — | — | ↗ |
| 2022-09-20 | RICHMAN ERIC I | Director | A-Award | A | Restricted Stock Units | 54,900 | 0.00 | — | 54,900 | — | ↗ |
| 2022-09-20 | Nicaise Claude | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 3.50 | 36.8K | 10,500 | — | ↗ |
| 2022-09-20 | Melincoff Gwen A | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 3.50 | 36.8K | 10,500 | — | ↗ |
| 2022-09-20 | Islam Khalid | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 3.50 | 36.8K | 10,500 | — | ↗ |
| 2022-07-15 | Calabrese Salvatore | Officer | A-Award | A | Restricted Stock Units | 9,900 | 0.00 | — | 9,900 | — | ↗ |
| 2022-07-15 | Alder Matthias | Officer | A-Award | A | Employee Stock Option (right to buy) | 79,200 | 0.00 | — | 79,200 | — | ↗ |
| 2022-05-25 | RICHMAN ERIC I | Director / Officer | P-Purchase | A | Common stock | 2,482 | 2.58 | 6.4K | 217,729 | — | ↗ |
| 2022-05-19 | RICHMAN ERIC I | Director / Officer | P-Purchase | A | Common Stock | 9,256 | 2.83 | 26.2K | 215,247 | — | ↗ |
| 2022-05-19 | Calabrese Salvatore | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 8,100.00 | 24.30M | 0 | — | ↗ |
| 2021-12-23 | Alder Matthias | Officer | A-Award | A | Non Qualified Stock Option (right to buy) | 200,000 | 5.86 | 1.17M | 200,000 | — | ↗ |
| 2021-08-16 | RICHMAN ERIC I | Director / Officer | P-Purchase | A | Common Stock | 4,922 | 7.87 | 38.7K | 216,820 | — | ↗ |
| 2021-03-17 | Riley Jeffrey Scott | Director | — | D | Stock Option | 10,000 | 3.37 | 33.7K | 0 | — | ↗ |
| 2021-03-17 | RICHMAN ERIC I | Officer | — | D | Common Stock | 0 | 0.00 | — | 211,898 | — | ↗ |
| 2021-03-17 | Nicaise Claude | Director | — | D | Stock Option | 10,000 | 3.37 | 33.7K | 0 | — | ↗ |
| 2021-03-17 | Melincoff Gwen A | Director | — | D | Stock Option | 10,000 | 3.37 | 33.7K | 0 | — | ↗ |
| 2021-03-17 | Islam Khalid | Director | — | I | Common Stock | 0 | 0.00 | — | 880,784 | — | ↗ |
| 2021-03-17 | HASLER HANS PETER | Director | — | D | Stock Option | 10,000 | 3.37 | 33.7K | 0 | — | ↗ |
| 2021-03-17 | GOLDSTEIN DOV A MD | Director | — | D | Stock Option | 10,000 | 3.37 | 33.7K | 0 | — | ↗ |
| 2021-03-17 | Calabrese Salvatore | Officer | — | D | Stock Option | 83,674 | 3.37 | 282.0K | 0 | — | ↗ |
| 2021-03-17 | Bellotto Manolo | Officer | — | D | Stock Option | 123,309 | 3.37 | 415.6K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
42.65M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gene Mack Chief Executive Officer | 500.0K | — | — | 802.8K | 150.0K | 14.3K | 1.47M | 54.72% | ↗ |
| 2 | 2025 | Gianluca Fuggetta Principal Financial Officer | 241.4K | — | — | 82.0K | 21.7K | — | 345.1K | 23.76% | ↗ |
| 3 | 2024 | Matthias Alder Former Chief Executive Officer | 262.5K | — | — | 1.03M | 125.0K | 24.5K | 1.44M | 71.48% | ↗ |
| 4 | 2024 | Gene Mack Chief Executive Officer | 270.6K | — | — | 455.7K | — | 11.4K | 737.7K | 61.77% | ↗ |
| 5 | 2024 | Gianluca Fuggetta Principal Financial Officer | 204.5K | — | — | 139.6K | 23.9K | — | 367.9K | 37.93% | ↗ |
| 6 | 2024 | C. Evan Ballantyne Former Chief Financial Officer | 58.3K | — | — | — | — | 10.8K | 69.1K | 0.00% | ↗ |
| 7 | 2023 | Matthias Alder Chief Executive Officer | 500.0K | — | 317.7K | 527.7K | 125.0K | 44.4K | 1.51M | 55.81% | ↗ |
| 8 | 2023 | Matthias Alder Former Chief Executive Officer | 500.0K | — | 317.7K | 527.7K | 125.0K | 44.4K | 1.51M | 55.81% | ↗ |
| 9 | 2023 | C. Evan Ballantyne Former Chief Financial Officer | 254.1K | — | 454.0K | 343.0K | — | 22.7K | 1.07M | 74.22% | ↗ |
| 10 | 2023 | Salvatore Calabrese Former Chief Financial Officer | 88.1K | — | 105.9K | 175.9K | — | 293.1K | 663.0K | 42.50% | ↗ |
| 11 | 2023 | Gianluca Fuggetta Principal Financial Officer | 167.0K | — | — | 52.8K | 10.9K | — | 230.7K | 22.88% | ↗ |
| 12 | 2022 | Eric I. Richman Former Chief Executive Officer | 343.2K | — | 192.2K | 622.6K | — | 115.9K | 1.27M | 64.06% | ↗ |
| 13 | 2022 | Matthias Alder Chief Executive Officer and former Chief Operating Officer | 444.7K | — | 88.6K | 394.2K | 125.0K | 23.3K | 1.08M | 44.87% | ↗ |
| 14 | 2022 | Matthias Alder Chief Executive Officer | 444.7K | — | 88.6K | 394.2K | 125.0K | 23.3K | 1.08M | 44.88% | ↗ |
| 15 | 2022 | Salvatore Calabrese Former Chief Financial Officer | 250.6K | — | 39.7K | 176.4K | 45.8K | — | 512.5K | 42.17% | ↗ |
| 16 | 2021 | Matthias Alder Chief Executive Officer and former Chief Operating Officer | 83.3K | — | — | 848.8K | 21.9K | — | 954.0K | 88.97% | ↗ |
| 17 | 2021 | Matthias Alder Chief Operating Officer | 83.3K | — | — | 848.8K | 21.9K | — | 954.0K | 88.97% | ↗ |
| 18 | 2021 | Eric I. Richman Former Chief Executive Officer | 373.5K | 80.0K | — | — | 120.0K | 26.7K | 600.2K | 0.00% | ↗ |
| 19 | 2021 | Eric I. Richman Chief Executive Officer | 373.5K | 80.0K | — | — | 120.0K | 26.7K | 600.2K | 0.00% | ↗ |
| 20 | 2021 | Salvatore Calabrese Former Chief Financial Officer | 268.0K | 40.0K | — | — | 37.4K | — | 345.4K | 0.00% | ↗ |
| 21 | 2021 | Salvatore Calabrese Chief Financial Officer | 268.0K | 40.0K | — | — | 37.4K | — | 345.4K | 0.00% | ↗ |
| 22 | 2020 | Salvatore Calabrese Chief Financial Officer | 41.8K | 21.1K | — | 202.3K | 25.1K | 29.1K | 319.4K | 63.33% | ↗ |
| 23 | 2020 | Eric I. Richman Chief Executive Officer | 131.3K | 30.0K | — | 63.8K | 37.5K | 14.5K | 277.1K | 23.04% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gene Mack | President, Chief Executive Officer & Director | 664.3K | male |
| Gianluca Fuggetta | Senior Vice President of Finance & Principal Financial Officer | 263.1K | male |
| Khalid Islam | Chairman & Founder | 75.0K | — |
| Joanne Taylor | Senior Vice President of Research | — | — |
| Jonas Hannestad | Chief Medical Officer | — | — |
| Terenzio Ignoni | Senior Vice President of Technical Operations | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GANX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
